Defining early recurrence in patients with resected primary colorectal carcinoma and its respective risk factors

Felix Wiesmueller 1 · Rolf Schuetz 1 · Melanie Langheinrich 1 · Maximilian Brunner 1 · Georg F. Weber 1 · Robert Grützmann 1 · Susanne Merkel 1 · Christian Krautz 1

Accepted: 8 January 2021 / Published online: 15 January 2021 © The Author(s) 2021

Abstract

Purpose There is no evidence-based definition of early recurrence following resection of colorectal cancer. The purpose of this study is to define a point that discriminates between early and late recurrence in patients who have undergone colorectal cancer resection with curative intent and to analyze associated risk factors.

Methods A retrospective single-center cohort study was performed at a university hospital recognized as a comprehensive cancer center, specializing in colorectal cancer surgery. Patient data were retrieved from a prospectively maintained institutional database. Included patients underwent resection for primary, non-metastatic colorectal carcinomas with curative intent between 1995 and 2010. Aims of the study were (1) to define the optimal cut-off point of recurrence-free survival based on overall survival using a minimum p value approach and (2) to identify patterns of initial recurrence and putative risk factors for early recurrence using regression models.

Results Recurrence was diagnosed in 412 of 1893 patients. Statistical analysis suggested that a recurrence-free survival of 16 months could be used to distinguish between early and late recurrence based on overall survival (p < 0.001). Independent risk factors for early recurrence included advanced pT categories (pT3,4/ypT3,4) and positive lymph node status (pN+/ypN+). Early recurrence was independent of site of recurrence and was associated with worse prognosis.

Conclusions Recurrence of colorectal carcinoma within 16 months after primary treatment should be labeled as “early.” Tumor categories pT3,4/ypT3,4 and positive lymph node status pN+/ypN+ are predictive of early recurrence.

Keywords Colorectal cancer · Colorectal carcinoma · Cancer recurrence · Recurrence group · Follow-up · Hemicolectomy · Low anterior resection

Introduction

Colorectal cancer (CRC) has the third highest tumor incidence in both men and women, making it one of the most common malignancies. A combined mortality rate of 14.2% renders this entity the second most common cause of cancer-related deaths [1]. Therapy depends on tumor stage and typically consists of surgical resection, which may be combined with other treatment modalities, such as chemotherapy or radiation. During post-treatment surveillance, patients are monitored with regular physical examination, measurement of tumor markers, imaging studies, and endoscopies [2]. Patients with recurrence may benefit from additional therapy [3]. Major medical association guidelines categorize follow-up schedules in an early period with more frequent examinations and a late period with less frequent examinations. However, evidence-based distinction of recurrence groups in CRC is currently lacking [2].

Several studies have used a minimum p value approach to determine cutoff points for defining recurrence groups in other tumor entities [4–6]. We hypothesized that patients with CRC recurrence following primary resection can be dichotomized into an early and a late recurrence group based on their respective survival. To achieve this, we intended to use a minimum p value approach. Additionally, we intended to examine risk factors that might be associated with the resulting recurrence groups.
Material and methods

Patient data

This retrospective study was performed at the Department of Surgery, University Hospital Erlangen, Friedrich-Alexander-University of Erlangen-Nuremberg (FAU), Germany. It was approved by the local Ethics Commission (submission ID: 414_18 Be). All patient information was retrieved from the Erlangen Registry for Colorectal Carcinomas (ERCRC), an institutional database that is maintained in a prospective manner. Patient data included epidemiologic parameters, clinical findings, treatment history, imaging results, histologic results, and follow-up data collected either at the university hospital, or from family physicians of patients via mailed questionnaires for at least 5 years. Follow-up was performed at 3-month intervals for the first 2 years, and at 6-month intervals thereafter. In 2004, follow-up intervals were changed to 6-month intervals for the first 2 years and then yearly for the following 3 years, in accordance with the first edition of the German Evidence-based Guideline for Colorectal Cancer [7]. After 5 years of tumor-free follow-up, ERCRC contacted patients at their local registration by telephone to check for their status (living or deceased).

Aims and criteria

The aim of the study was to analyze a cohort of patients with local and/or distant recurrence following surgical resection of primary, not metastasized carcinoma of the colon or rectum between 1995 and 2010. Primary endpoints were recurrence-free survival (RFS) and overall survival (OS). Secondary aims were (1) to assess demographic, clinicopathologic and treatment characteristics of the patient collective and (2) to perform logistic regression on these characteristics in order to identify possible risk factors for early recurrence.

Inclusion criteria were solitary invasive colorectal carcinoma (tumor stages T1 and above), treatment by hemicolectomy with complete mesocolic excision (CME) [8], extended hemicolectomy with CME, low anterior resection, intersphincteric resection or abdominoperineal excision with total mesorectal excision (TME) [9] at the Department of Surgery of the University Hospital Erlangen, treatment between 1995 and 2010, macroscopic curative resection (R0, R1), no other previous or synchronous malignancies, no history of familial adenomatous polyposis, ulcerative colitis or Crohn’s disease, no distant metastases, no watch and wait strategy with secondary resection. Exclusion criteria were surgery-related mortality, death within 90 days of operation, unknown tumor status, < 84 months of follow-up without recurrence or death.

Clinical and pathological variables

The primary tumor was categorized as rectal if located ≤16 cm from the anal verge when measured with a rigid rectosigmoidoscope. Primary colorectal tumors located proximal to this limit were categorized as colonic tumors. Patients were assorted to pT1,2/ypT0,1,2, pT3,4/ypT3,4, pN0/ypN0, or pN+/ypN+ groups according to their respective TNM stage. The TNM stage was determined as specified by the UICC/ AJCC Cancer Staging Manual, 8th Edition [10]. Treatment was divided into either “surgery only” or “multimodal,” if patients received any form of additional therapy pre- or post-operatively, e.g., chemotherapy. Surgery was considered elective if patients were regularly admitted for a planned procedure, contrary to emergent procedures, defined as the need for urgent surgery within 48 h of admission [11]. The American Society of Anesthesiologists (ASA) scoring system was applied preoperatively to assess the overall fitness of patients and documented in the patient chart. These retrieved ASA scores, if available, were grouped as either ASA 1–2 or ASA 3–4. CEA concentrations of ≥5 ng/ml were considered pathologically elevated. Resection margins were rated as either R0 (free resection margins) or R1 (microscopically positive margins) after histopathologic workup. The histomorphologic diagnosis of this workup was recorded as either adenocarcinoma or mucinous/signet ring cell carcinoma. Postoperative complications were defined as a deviation from the normal postoperative course requiring treatment.

Recurrences

Our institutional follow-up strategy adhered to national guidelines [12]. Symptomatic as well as asymptomatic recurrences were recorded. The first occurrence/event of recurrence was analyzed. Recurrent disease was classified as “local,” “distant,” (metastases) or “both” according to restaging results from follow-up imaging. Distant sites of recurrence were further stratified into “liver metastases,” “pulmonary metastases,” “other sites,” or “multiple sites of metastases.” The study collective was further assessed according to gender (male / female), age at time of diagnosis (< 65 years / ≥ 65 years of age), and date of procedure (1995–2003 / 2004–2010).

Statistical analysis

The overall survival (OS) was calculated from the start of primary treatment to either death or date of last follow-up. The recurrence-free survival (RFS) was defined as the period between procedure and date of first locoregional and/or distant recurrence. A minimum p value approach was used to identify patterns of recurrence assuming that there are two groups of recurrence defined by a single cut-off point in time. In order to define the optimal cut-off point, a piecewise regression with
log-rank tests was performed to compare OS of early and late recurrence groups at different thresholds. These thresholds were formulated in progressing steps of 3 months, starting at 6 months until a maximum of 60 months after the procedure. Median OS was calculated for both putative recurrence groups at each cut-off value. The lowest resulting \( p \) value was chosen as an optimal cut-off point. Potential risk factors for early colorectal recurrence were assessed by logistic regression. Cox’s proportional hazard model was used to assess risk factors for OS. Variables that showed an association with a \( p \) value of <0.05 in univariate analysis were included as covariates in a multivariate regression model. Results of both analyses were displayed as odds ratios (OR) or hazard ratios (HR) with their corresponding 95% confidence interval (CI). Statistical significance was defined as \( p < 0.05 \). We used the STROBE cohort checklist when writing our report [13]. The Sankey diagram was created with Tableau Desktop 2019.2 (Tableau Software, Seattle, WA). The minimum \( p \) value graph was plotted using Microsoft Excel 2011 (Microsoft Corp., Redmond, WA). All other graphs and statistical analyses were prepared with SPSS 21.0 software (IBM Corp., Armonk, NY).

Results

Patient cohort

A total of 1893 patients were included in the study. Two hundred sixty-two patients had rectal cancer, 150 patients had colonic cancer. Twenty (1.1%) patients were excluded due to unknown tumor status. Four hundred twelve (21.8%) patients developed recurrence. These patients were further analyzed. The median OS for all patients with recurrence was 58 months (95% CI 14–198 months). The median RFS of the cohort was 21 months (95% CI 5–83 months). At the time of analysis 348 patients (84.5%) had died. Further clinicopathologic characteristics are summarized in Table 1.

Early and late recurrence

The optimal cut-off point of RFS to differentiate between an early and a late recurrence group based on the overall prognosis was found to be at 16 months after primary treatment. The early recurrence group consisted of 157 patients, while the late recurrence group included 255 patients. Median OS of the early recurrence group was 33 months, while the late recurrence group had a median OS of 77 months \( (p < 0.001) \). Five-year post-recurrence survival of the early recurrence group was 18.5% (95% CI 12.4–24.6) vs. 31.6% (25.7–37.5) of the late recurrence group \( (p = 0.004) \).

Results of the minimum \( p \) value approach are shown in Table 2. Additionally, a graph was plotted to demonstrate the trend of \( p \) values along the progressing putative thresholds with a nadir at 16 months (Fig. 1).

Recurrence patterns

Most recurrences arise from rectal carcinomas followed by primary tumors of the left and right colon (Fig. 2). This composition of recurrences is distributed similarly among early and late recurrence groups. Colonic carcinomas are most likely to recur as distant metastases, and less likely to recur as local or simultaneous local and distant recurrences. Recurrence-free survival was not influenced by the location of recurrent tumors (Fig. 3). Overall survival and recurrence-free survival were similar between location of primary tumors when dividing into early and late recurrence groups (Fig. 4).

Risk factor assessment

Univariate analysis showed that advanced pT category (pT3/4/ypT3,4: OR 2.1, 95% CI 1.3–3.4, \( p = 0.005 \)), positive lymph node status (pN+/ypN+: OR 2.4, 95% CI 1.6–3.6, \( p < 0.001 \)), and positive resection margins (R1: OR 4.5, 95% CI 1.2–17.3, \( p = 0.028 \)) were significantly associated with early recurrence (<16 months) (Table 3). On multivariate analysis, advanced pT category (OR 1.8, 95% CI 1.1–3.0, \( p = 0.029 \)) and positive lymph node status (OR 2.2, 95% CI 1.4–3.3, \( p < 0.001 \)) proved to be independent risk factors (Table 3).

An additional Cox regression analysis of overall survival in all patients (Table 4) showed that R1 resection margins versus R0 margins (HR 2.0, 95% CI 1.0–3.8, \( p = 0.038 \)) and locoregional plus distant metastases (HR 3.7, 95% CI 2.3–5.8, \( p < 0.001 \)) or multiple sites of metastases (HR 2.7, 95% CI 1.8–3.9, \( p < 0.001 \)) versus pulmonary metastases alone significantly shortened OS. Late recurrences were also associated with a significantly longer OS compared to early recurrences (HR 0.4, 95% CI 0.3–0.5, \( p < 0.001 \)).

Discussion and conclusion

The purpose of postoperative follow-up in cancer patients is to detect tumor recurrence, allowing for timely treatment, and, ultimately, improving survival. Unfortunately, there is little robust data about recurrences in CRC and no evidence-based definition for early recurrence after resection. Our study observed that the optimal cut-off value to differentiate between early and late recurrences, based on overall prognosis, is 16 months. Consequently, postoperative recurrence up to an interval of 16 months is linked to poor OS, as evident in the median OS of 33 months of early recurrences compared to a median OS of 77 months of late recurrences. Likewise, 5-year...
post-recurrence survival was lower in the early recurrence group (18.5%) than in the late recurrence group (31.6%).

Within the published literature, postoperative cut-off points that help differentiate between early and late recurrence have been chosen arbitrarily and vary from 1 to 5 years [14–19]. Our study observed that the optimal cut-off value to differentiate between early and late recurrences, using a minimum p value approach based on overall prognosis, is 16 months. Grooth et al. [4] recently used a minimum p value approach to define recurrence groups...
in pancreatic cancer. They underlined that for the minimum p value approach they consciously chose the post-recurrence survival (PRS) because OS times in the late recurrence group would potentially introduce bias due to

| Evaluated cutoff point (months) | $P$ value  | Potential early recurrence group | Potential late recurrence group |
|--------------------------------|------------|----------------------------------|--------------------------------|
| < 6                            | 0.000085   | 32 21                            | 380 62                         |
| < 9                            | 1.288×10^{-7} | 67 25                           | 345 65                         |
| < 12                           | 3.35×10^{-12}| 102 30                          | 310 69                         |
| < 13                           | 2.908×10^{-15}| 117 30                         | 295 72                         |
| < 14                           | 1.862×10^{-14}| 131 32                         | 281 73                         |
| < 15                           | 2.818×10^{-15}| 140 32                         | 272 75                         |
| < 16                           | 2.467×10^{-17}| 157 33                         | 255 77                         |
| < 17                           | 8.119×10^{-14}| 170 34                         | 242 77                         |
| < 18                           | 1.03×10^{-13}| 178 34                          | 234 77                         |
| < 21                           | 6.931×10^{-11}| 204 36                         | 208 78                         |
| < 24                           | 6.234×10^{-10}| 223 38                         | 189 80                         |
| < 27                           | 7.551×10^{-8} | 250 39                         | 162 83                         |
| < 30                           | 1.842×10^{-8} | 264 40                         | 148 86                         |
| < 33                           | 1.556×10^{-9} | 283 40                         | 129 92                         |
| < 36                           | 3.553×10^{-9} | 301 43                         | 111 101                        |
| < 39                           | 1.956×10^{-8} | 313 46                         | 99 102                         |
| < 42                           | 1.368×10^{-7} | 327 48                         | 85 104                         |
| < 45                           | 5.616×10^{-7} | 331 49                         | 81 104                         |
| < 48                           | 0.000003    | 336 49                          | 76 103                         |
| < 51                           | 0.000002    | 347 49                          | 65 106                         |
| < 54                           | 6.474×10^{-7} | 360 52                         | 52 110                         |
| < 57                           | 4.594×10^{-7} | 361 52                         | 51 110                         |
| < 60                           | 0.000001    | 364 52                          | 48 117                         |

Optimal cut-off point with lowest $p$ value is marked in italics; $n$ indicates the number of patients in each potential recurrence group; OS, overall survival

Fig. 1 Optimal cut-off point displayed by the course of different cutoff points with corresponding $p$ values plotted on a logarithmic scale. The optimal cutoff threshold at 16 months (circled in red) distinguishes between an early and a late recurrence group in terms of the overall survival.
a longer recurrence-free interval. As this bias may apply for diseases with short post-recurrence survival times, such as pancreatic cancer, it is unlikely in diseases with numerous treatment options for recurrent disease and longer post-recurrence survival times, such as colorectal cancer. In addition, RFS, OS, and PRS are not inversely related in CRC. Based on these considerations, we elected to use the difference in overall survival in our analyses to define early and late recurrence.

A recent meta-analysis by Zhao et al. [20] suggests that intense follow-up does improve OS compared to less intense follow-up care. Meester et al. [21] conducted a microsimulation model where they compared benefits and costs of different surveillance models of patients who had undergone removal of colorectal adenomas. Their model suggests that high-intensity surveillance as recommended in the US provides modest but clinically relevant benefits over low-intensity surveillance at acceptable cost. However, guidelines by the German Guideline Recommendation Group Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF) [12], the National Comprehensive Cancer Network (NCCN) [22], the European Society for Medical Oncology (ESMO) [23, 24], and the American Society of Clinical Oncology (ASCO) [25] vary in their recommendations for the initial period of intensive follow-up. On average, they advocate an intensive surveillance using history taking, physical exam, CEA concentrations, CT scans and endoscopies for up to 3 years after resection and a less intense follow-up thereafter. The definition of potential early and late recurrence groups is of paramount importance to determine adequate risk-adjusted follow-up strategies that also account for economic feasibility [3].

The impact of timing of recurrence revealed in this study may help to improve survival in two ways. First, it allows for a refinement of follow-up strategies through a more precise definition of patients that are at risk of early recurrence. Second, it may aid in decision-making regarding the treatment of recurrence through better prognostic stratification, as late recurrence is associated with higher percentage of 5-year post-

Fig. 2 Sankey diagram of colorectal recurrences illustrating the proportions of recurrent colorectal tumors (rectum, left colon, right colon) that are diagnosed within (early) or after (late) 16 months following primary treatment as well as their corresponding sites of recurrence (Local Recurrence, Distant Metastases, Both). All primary tumors appear to be evenly distributed among early and late recurrence groups. Colonic tumors contribute more to distant metastases than to local or both (local + distant) recurrences. N indicates the number of respective cases; * total number of treated patients: rectum = 1003, left colon = 517, right colon = 353

Fig. 3 Kaplan-Meier estimator for comparison of site of recurrence and recurrence-free survival. There is no specific site that is favorable of early recurrence
recurrence survival and longer OS. For example, instead of treating a singular liver lesion with resection only it might be treated with additional chemotherapy if diagnosed within 16 months after primary resection.

In accordance with the current literature [14, 16, 17, 19, 26], this study identified advanced depth of invasion (pT3,4/ypT3,4) and positive lymph node status (pN+/ypN+) as independent risk factors that are associated with early recurrence of CRC. R1 resection margins were discovered to be a risk factor for early recurrence by univariate analyses. However, statistical significance was not reached in multivariate analysis, likely due to the small number of patients with R1 resection ($p = 0.057$). Positive resection margins signify microscopically visible groups of tumor cells up to the resection margin. The remaining portion of malignant cells in the body could develop faster into a noticeable tumor bulk than single metastatic cells since tumor growth is exponential. From this mechanistic perspective, it makes sense to consider R1 margins as a risk factor for early recurrence. Future studies with larger patient cohorts might be able to clarify this issue.

CRC guidelines approve screening for increased serum CEA concentrations during follow-up until 3–5 years after
Nevertheless, there is some controversy regarding the value of CEA surveillance [2]. It seems to be a prognostic risk factor for systemic recurrence, especially of liver metastases. Yet, it has not been shown to be prognostic for locoregional recurrence and has an inverse correlation with tumor grade. Elevated levels are also seen in patients with chronic renal failure and smokers [27]. In this study, CEA was not identified as a risk factor. However, CEA values were missing in 79 (19.2%) patients.

For the refinement of follow-up strategies, it is essential to understand associations between the sites and the timing of recurrences as well as the respective prognosis. We observed that primary colonic and rectal carcinomas had similar RFS and OS curves with early recurrences having a worse outcome.

### Table 3: Logistic regression on risk of early recurrence (< 16 months cutoff), 157 of 412 patients total

| Risk factors                        | Univariate analysis | Multivariate analysis |
|-------------------------------------|---------------------|-----------------------|
|                                     | n                   | Odds ratio  | 95% CI | P value | Odds ratio  | 95% CI | P value |
| Gender                              |                     |            |       |         |            |       |        |
| Male                                | 271                 | 1.0        | 0.9–2.0 | 0.181   | 1.0        | 0.9–2.0 | 0.181   |
| Female                              | 141                 | 1.3        |         |         | 1.0        |         |         |
| Age at time of diagnosis (years)    |                     |            |       |         |            |       |        |
| < 65                                | 211                 | 1.0        |         |         | 1.0        |         |         |
| ≥ 65                                | 201                 | 1.1        | 0.7–1.6 | 0.625   | 1.1        | 0.7–1.6 | 0.625   |
| Location of primary tumor           |                     |            |       |         |            |       |        |
| Colon                               | 150                 | 1.1        |         |         | 1.1        |         |         |
| Rectum                              | 262                 | 1.0        | 0.7–1.6 | 0.698   | 1.0        | 0.7–1.6 | 0.698   |
| pT category*                        |                     |            |       |         |            |       |        |
| pT1,2/ypT0,1,2                       | 97                  | 1.0        |         |         | 1.0        |         |         |
| pT3,4/ypT3,4                        | 315                 | 2.1        | 1.3–3.4 | 0.005   | 1.8        | 1.1–3.0 | 0.029   |
| pN category*                        |                     |            |       |         |            |       |        |
| pN0/ypN0                            | 195                 | 1.0        |         |         | 1.0        |         |         |
| pN+/ypN+                            | 217                 | 2.4        | 1.6–3.6 | < 0.001 | 2.2        | 1.4–3.3 | < 0.001 |
| Time of surgery                     |                     |            |       |         |            |       |        |
| 1995–2003                           | 257                 | 1.0        |         |         | 1.0        |         |         |
| 2004–2010                           | 155                 | 0.9        | 0.6–1.4 | 0.665   | 0.9        | 0.6–1.4 | 0.665   |
| Treatment                           |                     |            |       |         |            |       |        |
| Surgery only                        | 181                 | 1.0        |         |         | 1.0        |         |         |
| Multimodal treatment                | 231                 | 1.5        | 1.0–2.2 | 0.067   | 1.5        | 1.0–2.2 | 0.067   |
| Type of admission                   |                     |            |       |         |            |       |        |
| Elective surgery                    | 382                 | 1.0        |         |         | 1.0        |         |         |
| Emergency surgery                   | 30                  | 1.7        | 0.8–3.6 | 0.167   | 1.7        | 0.8–3.6 | 0.167   |
| ASA score†                          |                     |            |       |         |            |       |        |
| 1–2                                 | 309                 | 1.0        |         |         | 1.0        |         |         |
| 3–4                                 | 77                  | 0.9        | 0.7–1.2 | 0.588   | 0.9        | 0.7–1.2 | 0.588   |
| CEA concentration (ng/ml)††         |                     |            |       |         |            |       |        |
| < 5                                 | 235                 | 1.0        |         |         | 1.0        |         |         |
| ≥ 5                                 | 98                  | 1.6        | 1.0–2.6 | 0.053   | 1.6        | 1.0–2.6 | 0.053   |
| Resection margin                    |                     |            |       |         |            |       |        |
| R0                                  | 401                 | 1.0        |         |         | 1.0        |         |         |
| RI                                  | 11                  | 4.5        | 1.2–17.3| 0.028   | 3.7        | 1.0–14.6| 0.057   |
| Histomorphology                     |                     |            |       |         |            |       |        |
| Adenocarcinoma                      | 372                 | 1.0        |         |         | 1.0        |         |         |
| Mucinous carcinoma / signet-ring cell carcinoma | 40  | 1.1        | 0.6–2.1 | 0.795   | 1.1        | 0.6–2.1 | 0.795   |
| Postoperative complications         |                     |            |       |         |            |       |        |
| No complications                    | 301                 | 1.0        |         |         | 1.0        |         |         |
| Any complications                   | 111                 | 1.1        | 0.7–1.7 | 0.697   | 1.1        | 0.7–1.7 | 0.697   |
| Site of recurrence                  |                     |            |       |         |            |       |        |
| Locoregional                        | 43                  | 1.0        |         |         | 1.0        |         |         |
| Local and distant                   | 77                  | 1.3        | 0.6–2.7 | 0.562   | 1.3        | 0.6–2.7 | 0.562   |
| Liver metastases                    | 120                 | 1.4        | 0.7–2.9 | 0.335   | 1.4        | 0.7–2.9 | 0.335   |
| Pulmonary metastases                | 68                  | 0.8        | 0.3–1.8 | 0.546   | 0.8        | 0.3–1.8 | 0.546   |
| Other sites of metastases           | 39                  | 1.3        | 0.5–3.2 | 0.567   | 1.3        | 0.5–3.2 | 0.567   |
| Multiple sites of metastases        | 57                  | 0.9        | 0.4–2.0 | 0.728   | 0.9        | 0.4–2.0 | 0.728   |

Significant results are marked in italics; n indicates the number of patients; CI, confidence interval

*American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC) staging system [10]

†Three hundred eighty-six patients had preoperative American Society of Anesthesiologists (ASA) scores available for analysis

††Three hundred thirty-three patients had preoperative carcinoembryonic antigen (CEA) levels available for analysis

reseption of CRC [12, 22–25]. Nevertheless, there is some controversy regarding the value of CEA surveillance [2]. It seems to be a prognostic risk factor for systemic recurrence, especially of liver metastases. Yet, it has not been shown to be prognostic for locoregional recurrence and has an inverse correlation with tumor grade. Elevated levels are also seen in patients with chronic renal failure and smokers [27]. In this study, CEA was not identified as a risk factor. However, CEA values were missing in 79 (19.2%) patients.

For the refinement of follow-up strategies, it is essential to understand associations between the sites and the timing of recurrences as well as the respective prognosis. We observed that primary colonic and rectal carcinomas had similar RFS and OS curves with early recurrences having a worse
prognosis (Fig. 4). Early and late recurrences were evenly distributed among colonic and rectal carcinomas. Metastatic spread of primary tumors seemed to be more or less evenly distributed among anatomic locations with colonic tumors having a tendency to contribute more to distant metastases (Fig. 2). Combined metastases (locoregional and distant) or multiple sites of metastases were associated with decreased OS as compared to pulmonary metastases alone. Yet, early recurrence and recurrence-free survival were not influenced by the location of recurrent tumors.

Follow-up for CRC with focus on particular organs, e.g., targeted liver ultrasound, does not seem reasonable for the detection of early recurrences. Instead, our data support an intensive, whole body follow-up for patients at risk of early recurrences for at least 16 months after primary therapy. The use of risk factors for early recurrence, such as tumor extent or lymph node status, may enable a more individual adaption of follow-up strategies. Yet, there is still the need to develop better methods for detection of tumor recurrence in order to improve detection rates and, possibly, patient survival. Emerging prognostic markers, such as circulating tumor DNA (ctDNA) [28, 29], microRNA (miRNA) [30, 31], and circulating tumor cells [32] may help to improve monitoring of CRC recurrence.

This study has several limitations. Generally, the minimum \( p \) value approach may increase Type I error [33] and it was assumed that there is only one but not several cut-off points. The retrospective nature of this single-center study and the limited size of the patient cohort may contribute to additional bias. The cohort featured patients from a broad time frame (1995–2010). Primary treatment and therapy of tumor recurrences underwent significant changes at our institution during this period of time: FOLFOX and FOLFIRI chemotherapy regimens were launched from 1995 to 2004, while novel biologic agents, e.g., vascular endothelial growth factor (VEGF) antibodies and epidermal growth factor receptor (EGFR) inhibitors were introduced during 2005 and 2010 [34]. Hence, we included different time periods of surgery into our multivariate regression models to acknowledge the confounding effect of time-related changes.

### Conclusion

After primary resection of CRC, patients with advanced pT category and/or positive lymph node status are at risk of early recurrence that may be defined as recurrence within 16 months. Early recurrence is associated with worse prognosis. Site of recurrence is not related to early recurrence. Having a clear threshold of postoperative survival that defines recurrence would allow better risk-adapted follow-up strategies in the future.

### Acknowledgments

We thank Alexander Mou for providing a Tableau template for the Sankey diagram. The template can be accessed on his blog on data visualization (http://www.vizdiff.blogspot.com).

We thank Darren Bryan MD for critical reading.

### Authors’ contributions

Felix Wiesmueller, Susanne Merkel, Robert Grutzmann, and Christian Krautz contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Felix Wiesmueller, RolfSchuetz, Susanne Merkel and Christian Krautz. The first draft of the manuscript was written by Felix Wiesmueller and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

### Funding information

Open Access funding enabled and organized by Projekt DEAL.

### Data availability

Erlangen Registry for Colorectal Carcinomas (ERCRC).

### Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

---

### Table 4

| Risk factors | \( n \) | Hazard ratio | 95% CI | \( p \) value |
|--------------|-------|--------------|-------|------------|
| pT category* |       |              |       |            |
| pT1,2/ypT0,1,2 | 97    | 1.0          |       |            |
| pT3,4/ypT3,4  | 315   | 1.1          | 0.9–1.4 | 0.443      |
| pN category* |       |              |       |            |
| pN0/ypN0      | 195   | 1.0          |       |            |
| pN+/ypN+      | 217   | 1.2          | 1.0–1.5 | 0.069      |
| Resection margin |     |              |       |            |
| R0            | 401   | 1.0          |       |            |
| R1            | 11    | 2.0          | 1.0–3.8 | 0.038      |
| Site of recurrence |   |            |       |            |
| Pulmonary metastases | 68  | 1.0        |       |            |
| Locoregional recurrence | 43  | 1.3        | 0.9–2.0 | 0.154      |
| Locoregional+ distant metastases | 77  | 3.7        | 2.3–5.8 | < 0.001    |
| Liver metastases | 120  | 1.4        | 1.0–1.9 | 0.051      |
| Other sites of metastases | 39  | 1.3 | 0.9–2.0 | 0.193      |
| Multiple sites of metastases | 57  | 2.7 | 1.8–3.9 | < 0.001    |
| Time of recurrence |   |            |       |            |
| Early recurrence (< 16 months) | 157 | 1.0 |       |            |
| Late recurrence (> 16 months) | 255 | 0.4 | 0.3–0.5 | < 0.001    |

Significant results are marked in italics; \( n \) indicates the number of patients; CI, confidence interval

*American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC) staging system [10]
Ethics approval  Approved by the local Ethics Commission (submission ID: 414_18 Bc).

Consent to participate  Not applicable.

Consent for publication  Not applicable.

Code availability  Not applicable.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material, you will need to obtain permission directly from the copyright holder. To view a copy of this statutory regulation or exceeds the permitted use, you will need to obtain credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7–34. https://doi.org/10.3322/caac.201551

2. Liu SL, Cheung WY (2019) Role of surveillance imaging and endoscopy in colorectal cancer follow-up: quality over quantity? World J Gastroenterol 25(1):59–68. https://doi.org/10.3748/wjg.v25.i1.59

3. Adams K, Higgins L, Beazley S, Papagrigoriadis S (2015) Intensive surveillance following curative treatment of colorectal cancer allows effective treatment of recurrence even if limited to 4 years. Int J Color Dis 30(12):1677–1684. https://doi.org/10.1007/s00384-015-2356-x

4. Groot VP, Gemenetzis G, Blair AB, Rivero-Soto RJ, Yu J, Javed AA, Burkhart RA, Rinkes I, Molenaar IQ, Cameron JL, Weiss MJ, Wolfgang CL, He J (2019) Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg 269(6):1154–1162. https://doi.org/10.1097/SLA.0000000000002734

5. Imai K, Allard MA, Benitez CC, Vibert E, Sa Cunha A, Cherqui D, Castaing D, Baba H, Adam R (2016) Early recurrence after hepatectomy for colorectal liver metastases: what optimal delay is needed? Ann Surg 264(5):887–894. https://doi.org/10.1097/SLA.0000000000002169

6. Wang C, Pang S, Si-Ma H, Yang N, Zhang H, Fu Y, Yang G (2019) Specific risk factors contributing to early and late recurrences of intrahepatic cholangiocarcinoma after curative resection. World J Surg Oncol 17(1):2. https://doi.org/10.1186/s12957-018-1540-1

7. Schmiedel W, Pox C, Adler G, Fleig W, Folsch UR, Fruhmorgen P, Graeven U, Hohenberger W, Holstege A, Junginger T, Kuhlbacher K, Puls P, Rinkes I, Schmoll HJ, Zietz M, Selmbaum HK, Deussmann G (2004) S3-Guidelines Conference "Colorectal Carcinoma" 2004. Z Gastroenterol 42(10):1129–1177. https://doi.org/10.1055/s-2004-813609

8. Hohenberger W, Weber K, Matzel K, Papadopoulos T, Merkel S (2009) Standardized surgery for colonic cancer: complete mesocolic excision and central ligation–technical notes and outcome. Color Dis 11(4):354–364; discussion 364-355. https://doi.org/10.1111/j.1463-1318.2008.01735.x

9. Heald RJ, Husband EM, Ryall RD (1982) The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? Br J Surg 69(10):613–616. https://doi.org/10.1002/bjs.1800691019

10. AJCC Cancer Staging Handbook, 7th edn. Springer-Verlag, New York

11. Soreide ONJ, Fielding LP, Silen W (1997) Rectal cancer surgery: optimisation — standardisation — documentation vol international standardization and documentation of the treatment of rectal cancer, 1st edn. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60514-7

12. AWMF (2019) Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Kolorektales Karzinom, Langversion 2.1. http://www.leitlinien-programm-onkologie.de/leitlinien/kolorektal-karzinom/

13. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, Initiative S (2008) The strengthening of reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61(4):344–349. https://doi.org/10.1016/j.jclinepi.2007.11.008

14. Aghili M, Izadi S, Madani H, Mortazavi H (2010) Clinical and pathological evaluation of patients with early and late recurrence of colorectal cancer. Asia Pac J Clin Oncol 6(1):35–41. https://doi.org/10.1111/j.1743-7563.2010.01275.x

15. Cho YB, Chun HK, Yun HR, Lee WS, Yun SH, Lee WY (2007) Clinical and pathological evaluation of patients with recurrence of colorectal cancer five or more years after curative resection. Dis Colon Rectum 50(8):1204–1210. https://doi.org/10.1016/j.dcol.2007.09.027

16. Kobayashi H, Mochizuki H, Sugihara K, Morita T, Kotake K, Teramoto T, Kameoka S, Saito Y, Takahashi K, Hase K, Oya M, Maeda K, Hirai T, Kameyama M, Shirouzu K, Muto T (2007) Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. Surgery 141(1):67–75. https://doi.org/10.1016/j.surg.2006.07.020

17. Ryuk JP, Choi GS, Park JS, Kim HJ, Park SY, Yoon GS, Jun SH, Kwon YC (2014) Predictive factors and the prognosis of recurrence of colorectal cancer within 2 years after curative resection. Ann Surg Treat Res 86(3):143–151. https://doi.org/10.4174/asatr.2014.86.3.143

18. Tsai HL, Chu KS, Huang YH, Su YC, Wu YJ, Kuo CH, Chen CW, Wang JY (2009) Predictive factors of early relapse in UICC stage III colorectal cancer patients after curative resection. J Surg Oncol 100(8):736–743. https://doi.org/10.1002/jso.21404

19. Bouvier AM, Launoy G, Bouvier V, Rollot F, Manfredi S, Faire V, Coutet V, Jooste V (2015) Incidence and patterns of late recurrences in colon cancer patients. Int J Cancer 137(9):2133–2138. https://doi.org/10.1002/ijc.29578

20. Zhao Y, Yi C, Zhang Y, Fang F, Faramand A (2019) Intensive follow-up strategies after radical surgery for nonmetastatic colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS One 14(7):e0220533. https://doi.org/10.1371/journal.pone.0220533

21. Meester RGS, Lansdorp-Vogelaar I, Winawer SJ, Zauber AG, Knudsen AB, Ladabaum U (2019) High-intensity versus low-intensity surveillance for patients with colorectal adenomas: a cost-effectiveness analysis. Ann Intern Med 171(9):612–622. https://doi.org/10.7326/M19-2618

22. Benson AB 3rd, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffie S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofoceleut CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Gurski L, Freedman-Cass...
DA (2018) Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 16(7):874–901. https://doi.org/10.6004/jnccn.2018.0061

23. Glimelius B, Tired E, Cervantes A, Arnold D, Group EGW (2013) Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi81–vi88. https://doi.org/10.1093/annonc/mdt240

24. Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandala M, Cervantes A, Arnold D, Group EGW (2013) Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi64–vi72. https://doi.org/10.1093/annonc/mdt354

25. Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, Petrelli NJ, Ryan K, Schrag DH, Wong SL, Benson AB 3rd, American Society of Clinical O (2013) Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol 31(35):4465–4470. https://doi.org/10.1200/JCO.2013.50.7442

26. Kaiser AM, Kang JC, Chan LS, Beart RW (2006) The prognostic impact of the time interval to recurrence for the mortality in recurrent colorectal cancer. Color Dis 8(8):696–703. https://doi.org/10.1111/j.1463-1318.2006.01017.x

27. Ramphal W, Boeding JRE, van Iwaarden M, Schreinemakers JMJ, Rutten HJT, Crolla R, Gobardhan PD (2019) Serum carcinoembryonic antigen to predict recurrence in the follow-up of patients with colorectal cancer. Int J Biol Markers 34(1):60–68. https://doi.org/10.1111/ijm.12685

28. Lam M, Loree JM, Pereira AAL, Chun YS, Kopetz S (2018) Accelerating therapeutic development through innovative trial design in colorectal cancer. Curr Treat Options in Oncol 19(2):11. https://doi.org/10.1007/s11864-018-0524-2

29. Scholer L, Rieint T, Orntoft MW, Kassentoft CG, Arnaudottir SS, Vang S, Nordentoft I, Knudsen M, Lam Y, Andreasen D, Mortensen FV, Knudsen AR, Stribolt K, Sivessgaard K, Mouritzen P, Nielsen HJ, Laurberg S, Orntoft TF, Andersen CL (2017) Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer. Clin Cancer Res 23(18):5437–5445. https://doi.org/10.1158/1078-0432.CCR-17-0510

30. Oroso E, Ember I, Gombos K, Toth L, Tarpay A, Pap A, Otto S (2013) Alternatives for the intensive follow-up after curative resection of colorectal cancer. Potential novel biomarkers for the recommendations. Pathol Oncol Res 19(4):619–629. https://doi.org/10.1007/s12253-013-9672-7

31. Peng Q, Feng Z, Shen Y, Zhu J, Zou L, Shen Y, Zhu Y (2019) Integrated analyses of microRNA-29 family and the related combination biomarkers demonstrate their widespread influence on risk, recurrence, metastasis and survival outcome in colorectal cancer. Cancer Cell Int 19(1):1. https://doi.org/10.1186/s12935-019-0907-x

32. Wang D, Yang Y, Jin L, Wang J, Zhao X, Wu G, Zhang J, Kou T, Yao H, Zhang Z (2019) Prognostic models based on postoperative circulating tumor cells can predict poor tumor recurrence–survival in patients with stage II–III colorectal cancer. J Cancer 10(19):4552–4563. https://doi.org/10.7150/jca.30512

33. Altman DG, Lausen B, Sauerbrei W, Schumacher M (1994) Dangers of using “optimal” cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86(11):829–835. https://doi.org/10.1093/jnci/86.11.829

34. Merkel S, Schellerer VS, Wein A, Semrau S, Geppert C, Gohl J, Hohenberger W, Weber K, Grutzmann R (2018) The influence of tumour site on prognosis in metastatic colorectal carcinomas with primary tumour resection. Int J Colorectal Dis 33(9):1215–1223. https://doi.org/10.1007/s00384-018-3098-3

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.